Kawasaki Disease Coronary Artery Aneurysm Prevention trial
Does adding immediate corticosteroid treatment to standard of care (intravenous immunoglobulin and aspirin) prevent coronary artery aneurysm in Kawasaki disease patients?
What is this study about?
KD-CAAP is a multi-centre, randomised, open-label, blinded endpoint assessed trial, aiming to answer whether adding immediate corticosteroid treatment to standard of care intravenous immunoglobulin (IVIG) and aspirin will reduce coronary artery aneurysm rates in unselected Kawasaki disease patients across Europe, compared with IVIG and aspirin alone.
Type of study
Who is funding the study?
The trial is funded by the Innovative Medicines Initiative 2 Joint Undertaking that supports the conect4children research consortium.
Public and patient involvement is coordinated through Societi.
When is it taking place?
The trial opened in May 2019 and will run until April 2025. The deadline for recruitment is July 2024.
Where is it taking place?
The trial is run from 46 hospitals across 11 countries. These include Austria, Belgium, Estonia, Finland, France, Germany, Italy, The Netherlands, Spain, Sweden and the UK.
Who is included?
Children who aged between 30 days and 15 years who are diagnosed with Kawasaki disease through a set of clinical criteria or clinical criteria and laboratory assessments.